Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer

Clinical Lung Cancer

Volumn 12, Issue 6, 2011, Pages 350-359

  Pennell, Nathan A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Nonsmall cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VANDETANIB;

ALGORITHM; ALLERGIC REACTION; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80155190076     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.029     Document Type: Review

References (66)

1. World Health Organization Fact Sheet No. 310: The Top Ten Causes of Death [Web site.] http://www.who.int/mediacentre/factsheets/fs310-2008.pdf November 2008 Accessed October 8, 2009
2. American Cancer Society Cancer Facts & Figures, 2010 2010 American Cancer Society Atlanta, GA
3. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology™. Non-Small Cell Lung Cancer. V.2.2010 [Web site.] http://www.nccn.org/professionals/physician-gls/PDF/nscl.pdf Accessed April 8, 2010
4. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98 (Pubitemid 34438899)
5. O.S. Breathnach, B. Freidlin, and B. Conley Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results J Clin Oncol 19 2001 1734 1742 (Pubitemid 32230875)
6. C. Delbaldo, S. Michiels, and N. Syz Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis JAMA 292 2004 470 484 (Pubitemid 38988956)
7. J. Goffin, C. Lacchetti, and P.M. Ellis First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review J Thorac Oncol 5 2010 260 274
8. T. Lynch Jr, and E. Kim Optimizing chemotherapy and targeted agent combinations in NSCLC Lung Cancer 50 suppl 2 2005 S25 S32
9. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
10. FDA approves Avastin in combination with chemotherapy for first-line treatment of most common type of lung cancer Cancer Biol Ther 5 2006 1425 1428
11. F.R. Hirsch, R. Dziadziuszko, and D.R. Camidge Biomarker status correlates with clinical benefit: phase 2 study of single-agent erlotinib (E) or E intercalated with carboplatin and paclitaxel (ECP) in an EGFR biomarker-selected NSCLC population J Thorac Oncol 3 suppl 4 2008 S267
12. F.A. Shepherd, P.J. Rodrigues, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
13. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
14. M. Sibilia, R. Kroismayr, and B.M. Lichtenberger The epidermal growth factor receptor: from development to tumorigenesis Differentiation 75 2007 770 787 (Pubitemid 350086174)
15. R.S. Herbst, J.V. Heymach, and S.M. Lippman Lung cancer N Engl J Med 359 2008 1367 1380
16. A.F. Gazdar Personalized medicine and inhibition of EGFR signaling in lung cancer N Engl J Med 361 2009 1018 1020
17. F.R. Hirsch, M. Varella-Garcia, and F. Cappuzzo Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer Oncogene 28 suppl 1 2009 S32 S37
18. D.S. Salomon, R. Brandt, and F. Ciardiello Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
19. G.A. Silvestri, and M.P. Rivera Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists Chest 128 2005 3975 3984 (Pubitemid 43062660)
20. K. Suda, R. Onozato, and Y. Yatabe EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 4 2009 1 4
21. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
22. F. Cappuzzo, T. Ciuleanu, and L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
23. N. Thatcher, A. Chang, and P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537 (Pubitemid 41540110)
24. S.V. Sharma, D.W. Bell, and J. Settleman Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
25. R. De Boer, O. Arrieta, and M. Gottfried Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL) J Clin Oncol 27 2009 409s (abstract 8010)
26. D. Li, L. Ambrogio, and T. Shimamura BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
27. J.A. Engelman, K. Zejnullahu, and C.M. Gale PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib Cancer Res 67 2007 11924 11932
28. G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 2004 777 784 (Pubitemid 41103588)
29. R.S. Herbst, G. Giaccone, and J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794 (Pubitemid 41103589)
30. U. Gatzemeier, A. Pluzanska, and A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552 (Pubitemid 46733081)
31. R.S. Herbst, D. Prager, and R. Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
32. T. Li, P.N. Lara Jr, and P.C. Mack Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer Curr Drug Targets 11 2010 85 94
33. D.R. Gandara, A.M. Davies, and O. Gautschi Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies Clin Lung Cancer 8 suppl 2 2007 S61 S67
34. H. Shigematsu, and A.F. Gazdar Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers Int J Cancer 118 2006 257 262 (Pubitemid 41779062)
35. D.A. Eberhard, B.E. Johnson, and L.C. Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
36. M.S. Tsao, A. Sakurada, and J.C. Cutz Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144 (Pubitemid 41058345)
37. F.R. Hirsch, M. Varella-Garcia, and P.A. Bunn Jr Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 2006 5034 5042 (Pubitemid 46631407)
38. E.S. Kim, V. Hirsh, and T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
39. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
40. P.A. Janne, X.F. Wang, and M.A. Socinski Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 J Clin Oncol 28 2010 (abstract 7503)
41. O. Gautschi, P.C. Mack, and A.M. Davies Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions Clin Lung Cancer 9 suppl 3 2008 S129 S138
42. N. Normanno, C. Bianco, and L.A. De Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment Endocr Relat Cancer 10 2003 1 21 (Pubitemid 36457237)
43. T. Li, Y.H. Ling, and I.D. Goldman Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells Clin Cancer Res 13 2007 3413 3422 (Pubitemid 46944930)
44. C.M. Mahaffey, A.M. Davies, and P.N. Lara Jr Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation Clin Lung Cancer 8 2007 548 553 (Pubitemid 350292228)
45. D.B. Solit, Y. She, and J. Lobo Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel Clin Cancer Res 11 2005 1983 1989 (Pubitemid 40471864)
46. A.M. Davies, C. Ho, and L. Beckett Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation J Thorac Oncol 4 2009 862 868
47. T.S. Mok, Y.L. Wu, and C.J. Yu Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 27 2009 5080 5087
48. R.M. Gaafar, V. Surmont, and G. Scagliotti A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03) J Clin Oncol 28 2010 (abstract 7518)
49. J. Liang, M. Ahn, and J. Kang First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: an open-label, randomized phase II trial J Clin Oncol 28 2010 (abstract 7591)
50. C. Gridelli, F. Ciardiello, and R. Feld International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): the TORCH trial J Clin Oncol 28 2010 (abstract 7508)
51. T. Li, R. Gucalp, and B. Piperdi Pharmacodynamic separation (PDS) of pemetrexed and erlotinib versus pemetrexed monotherapy as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): first-stage analysis of a randomized phase II study J Thorac Oncol 4 2009 S304 S305 (abstract A6.2)
52. R. Rosell, G. Robinet, and A. Szczesna Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer Ann Oncol 19 2008 362 369 (Pubitemid 351201721)
53. R. Pirker, J.R. Pereira, and A. Szczesna Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 2009 1525 1531
54. T.J. Lynch, T. Patel, and L. Dreisbach Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 J Clin Oncol 28 2010 911 917
55. H. Lin, J. Jiang, and X. Liang Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis Lung Cancer 70 2010 57 62
56. R.S. Herbst, K. Kelly, and K. Chansky Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342 J Clin Oncol 28 2010 4747 4754
57. G.R. Blumenschein, R. Paulus, and W. Curran A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): a report of the 2 year and median survival (MS) for the RTOG 0324 trial J Thorac Oncol 3 2008 S263 S264 (abstract 3)
58. R. Govindan, J. Bogart, and X. Wang A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407 J Thorac Oncol 4 2009 S371 S372 (abstract C6.2)
59. E.S. Kim, R.S. Herbst, and J. Moon S0536: carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC), a SWOG phase II study J Thorac Oncol 4 2009 S455 (abstract PD3.5.5)
60. N. Hanna, R. Lilenbaum, and R. Ansari Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer J Clin Oncol 24 2006 5253 5258 (Pubitemid 46631370)
61. F.R. Hirsch, R.S. Herbst, and C. Olsen Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy J Clin Oncol 26 2008 3351 3357
62. O'Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. Oral presentation at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29 to June 2, 2009; Orlando, FL (abstract 8007).
63. S. Khambata-Ford, C.T. Harbison, and L.L. Hart Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer J Clin Oncol 28 2010 918 927
64. R.S. Herbst, Y. Sun, and W.E. Eberhardt Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Lancet Oncol 11 2010 619 626
65. J. Lee, V. Hirsh, and K. Park Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR) J Clin Oncol 28 2010 7525 (abstract 7525)
66. R.B. Natale, S. Thongprasert, and F.A. Greco Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST) J Clin Oncol 27 2009 409s (abstract 8009)